These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 6218507)

  • 1. An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness.
    Børup C; Meidahl B; Petersen IM; Vangtorp A; le Fèvre Honoré P
    Pharmacopsychiatria; 1982 Nov; 15(6):183-6. PubMed ID: 6218507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.
    Dunner DL; Cohn JB; Walshe T; Cohn CK; Feighner JP; Fieve RR; Halikas JP; Hartford JT; Hearst ED; Settle EC
    J Clin Psychiatry; 1992 Feb; 53 Suppl():57-60. PubMed ID: 1531827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine in the treatment of depression: a comparison with imipramine and placebo.
    Feighner JP; Boyer WF
    J Clin Psychiatry; 1992 Feb; 53 Suppl():44-7. PubMed ID: 1531824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients.
    Claghorn JL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():33-5. PubMed ID: 1531821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerance of femoxetine and imipramine in the treatment of depressive states. A randomized, double-blind study.
    Suominen J; Tamminen T; Elosuo R; Manniche PM
    Pharmacopsychiatry; 1988 Sep; 21(5):238-44. PubMed ID: 3067246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo- and imipramine-controlled study of paroxetine.
    Cohn JB; Crowder JE; Wilcox CS; Ryan PJ
    Psychopharmacol Bull; 1990; 26(2):185-9. PubMed ID: 2146697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled double-blind study of femoxetine and amitriptyline in patients with endogenous depression.
    Reebye PN; Yiptong C; Samsoon J; Schulsinger F; Fabricius J
    Pharmacopsychiatria; 1982 Sep; 15(5):164-9. PubMed ID: 6757983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of paroxetine.
    Boyer WF; Blumhardt CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():61-6. PubMed ID: 1531828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J; Aubin V
    Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First results of an open phase II study with the antidepressant paroxetine.
    Stuppäck C; Schubert H; Barnas C; Mair M; Schifferle I; Unterweger B; Wömhart L; Fleischhacker WW; Hinterhuber H
    Pharmacopsychiatry; 1988 Nov; 21(6):369-70. PubMed ID: 2977442
    [No Abstract]   [Full Text] [Related]  

  • 14. [Paroxetine in the treatment of depressive disorders (pilot study)].
    Svestka J; Novotný V; Kamenická V; Obrovská V; Cesková E
    Cesk Psychiatr; 1995 Jul; 91(3):135-42. PubMed ID: 7553946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled trial of paroxetine in the treatment of major depression.
    Smith WT; Glaudin V
    J Clin Psychiatry; 1992 Feb; 53 Suppl():36-9. PubMed ID: 1531822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
    Celada P; Pérez J; Alvarez E; Artigas F
    J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of paroxetine.
    Boyer WF; Feighner JP
    J Clin Psychiatry; 1992 Feb; 53 Suppl():3-6. PubMed ID: 1531819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
    Tulloch IF; Johnson AM
    J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression.
    Nemeroff CB
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):10S-17S. PubMed ID: 8106649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression.
    Rickels K; Amsterdam J; Clary C; Fox I; Schweizer E; Weise C
    J Clin Psychiatry; 1992 Feb; 53 Suppl():30-2. PubMed ID: 1531820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.